Editorial Comment

      This is an excellent clinical review of a large number of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-BP) during an almost 5-year period. All patients received ciprofloxacin, 500 mg twice daily for 5 days, starting 24 hours before the procedure. All patients underwent a minimum of a 12-core biopsy. The authors reviewed the infectious complications and noted that these occurred in 28 of 1339 patients (2.1%). A slightly greater (and statistically significant) incidence was found in patients undergoing repeat biopsy (6.8%) vs an initial biopsy (1.3%). Most of the patients (61%) had Escherichia coli as the cause of the infection, with 13 of 17 (76.5%) caused by extended-spectrum β-lactamase (ESBL)-producing bacteria. Of these, 10 of 17 (58.9%) were due to ESBL-producing E. coli. These infections were resistant to fluoroquinolone antibiotics.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Griffith B.C.
        • Morey A.F.
        • Ali-Khan M.
        • et al.
        Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk.
        J Urol. 2002; 168: 1021-1023
        • Tal R.
        • Livne P.M.
        • Lask D.M.
        • et al.
        Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy.
        J Urol. 2003; 169: 1762-1765
        • Carey J.M.
        • Korman H.J.
        Transrectal ultrasound guided biopsy of the prostate: do enemas decrease clinically significant complications?.
        J Urol. 2001; 166: 82-85
        • Feliciano J.
        • Teper E.
        • Ferrandino M.
        • et al.
        The incidence of fluoroquinolone resistant infections after prostate biopsy—are fluoroquinolones still effective prophylaxis?.
        J Urol. 2008; 179: 952-955
      1. American Urological Association Education and Research. Antibiotic Prophylaxis. Bethesda: American Urological Association Education and Research, Incorporated; Revised July, 2008.

      Linked Article